Kim et al. [35] previously reported that the combination of an inhibitor of glucose metabolism and afatinib in NSCLC resulted in a selective decrease in Mcl-1 expression through a translational control, mediated by the alteration of AMPK/mTOR signaling pathway. This evidence concerns the gene MCL1 and non-small cell lung carcinoma.